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Abstract
Background: In the present study, 2-tert-butyl-4-chloro-5-[6-(4-18F-fluorobutoxy)-pyridin-3-ylmethoxy]-2H-pyridazin-3-
one (18F-BCPP-BF), a PET probe for mitochondrial complex I (MC-I), was used to validate whether MC-I is a useful
biomarker for detecting acetaminophen-induced dysfunctions in the liver and kidney.
The kinetic and distribution of 18F-BCPP-BF were assessed in rats using high-resolution animal PET in vivo. The binding
specificity of 18F-BCPP-BF to MC-I in the liver and kidney was confirmed by the pre-administration of rotenone, a
specific MC-I inhibitor. The effects of acetaminophen on MC-I activity were assessed 2 and 24 h after the administration
of vehicle or acetaminophen at a dose of 100 or 300 mg/kg. Biochemical parameters in plasma and urine were
assessed 2, 6, and 24 h after the administration of vehicle or acetaminophen.
Results: The uptake of 18F-BCPP-BF by the liver and kidney was significantly inhibited by the pre-administration of
rotenone. Two and more hours after the administration of acetaminophen, the uptake of 18F-BCPP-BF was
dose-dependently reduced in the liver, even at 100 mg/kg, and in the kidney at 300 mg/kg, whereas biological
parameters started to be affected 6 h or later at doses of 300 mg/kg.
Conclusions: The present study demonstrated that 18F-BCPP-BF has potential as a PET probe for the quantitative
imaging of hepatic and renal dysfunction as impaired MC-I activity in the early phase of the treatment for an overdose
of acetaminophen in the living body with PET.
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Background
Mitochondria are present in every mammalian cell except
red blood cells and provide the majority of energy in the
form of adenosine triphosphate (ATP). Tissues with high
energy demands, such as the brain, heart, muscle, liver,
and kidney, contain the greatest number of mitochondria.
The electron transport chain in mitochondria, which con-
sists of five complexes from I to V, is the major site of
ATP production. Among these complexes, the complex I
(MC-I) is the first and rate-limiting step of the overall
respiratory activity and oxidative phosphorylation under
physiological conditions. Mitochondrial dysfunctions
contribute to the pathophysiologies of many acute and
chronic diseases. Mitochondria are also regarded as the
main intracellular source of reactive oxygen species
(ROS) in cells as well as a main target of ROS-mediated
damage.
Acetaminophen is a widely used antipyretic and analgesic
that is safe and effective when used at therapeutic dose
ranges; however, an overdose of acetaminophen induces
the etiology of acute hepatotoxicity [1, 2] and nephrotox-
icity [3]. The first reports of acetaminophen hepatotoxicity
in humans published in the 1960s [4] and acetaminophen
overdoses have since been identified as the most common
cause of acute liver failure in Western countries. In the
USA, an overdose of acetaminophen is responsible for
approximately 56,000 emergency room visits, 26,000
hospitalizations, and nearly 500 deaths each year [5].
The therapeutic dose range of acetaminophen is glu-
curonidated or sulfated for excretion, and its small
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amount is metabolized to N-acetyl-p-benzoquinone
imine (NAPQI), a chemically reactive intermediate, by
oxidation via cytochrome P450 2E1 (CYP2E1) [6]. At
therapeutic doses, NAPQI is readily detoxified by conjuga-
tion with glutathione, whereas an overdose of acetamino-
phen saturates the glucuronidation pathway. The resulting
excess amount of NAPQI was previously assumed to
react covalently with the sulfhydryl groups of cysteine
in glutathione and several proteins and decreases glutathi-
one levels, thereby contributing to increased oxidative/
nitrative stress [7].
However, recent studies revealed that the oxidative
modification of thiol molecules by NAPQI was minimal
in response to acetaminophen [8–11]. The immunoprecip-
itation of mitochondrial superoxide dismutase (MnSOD), a
critical enzyme in the detoxification of ROS, from the
livers of acetaminophen-treated mice did not detect
acetaminophen-MnSOD adducts [9]. These findings
suggest that the production of NAPQI is not the only
reason for acetaminophen-induced liver necrosis and
also that CYP2E1 may have a limited role in the forma-
tion of NAPQI at higher doses of acetaminophen [10].
Alternatively, acetaminophen has been reported to pro-
mote liver and kidney injury through enhanced protein ni-
tration due to increased levels of the reactive nitrogen
species, nitric oxide and peroxynitrite, which are formed
through the rapid reaction of superoxide with nitric oxide
[9, 11, 12]. Peroxynitrite is a nitrating and oxidizing agent
and is detoxified by glutathione [13]. Nitrated proteins in
mitochondria, such as aldehyde dehydrogenase, ATP syn-
thase, 3-ketoacyl-CoA thiolase, MnSOD, and glutathione
peroxidase, play a role in promoting acetaminophen-
induced mitochondrial dysfunction in the liver [12]. Of
these proteins, MnSOD in the mitochondrial matrix de-
toxifies the superoxide radical, and this is followed by the
formation of hydrogen peroxide and oxygen. Therefore,
MnSOD limits the reaction of superoxide with nitric oxide
to form the reactive nitrogen species peroxynitrite. Al-
though the effects of the nitration of proteins are poorly
understood at the molecular level, acetaminophen may
lead to a decrease in ATP synthase [10] and MnSOD
[9–11] activities through the nitration of Tyr residues
on their active sites [14]. The nitration of critical Tyr
residues in these enzymes results in their damage as well
as mitochondrial dysfunctions through the inactivation of
these activities by conformational changes [15]. In addition,
hepatotoxicity induced by peroxynitrite was found to be
markedly attenuated by the anti-oxidant glutathione [16]
and N-acetylcysteine (NAC), which functions by increasing
glutathione levels and binding with the reactive metabolite
of acetaminophen [16, 17]. Nitrative modifications to crit-
ical enzymes 2 h after the administration of acetaminophen
appear to contribute to mitochondrial dysfunctions, result-
ing in severe necrosis 24 h after its administration [10].
Most organs may be affected in mitochondrial cytopathies
that primarily affect oxidative phosphorylation. From the
renal point of view, since podocytes with abundant mito-
chondria have limited potency for regeneration, mitochon-
drial cytopathies induce irreversible podocyte damage and
microvascular lesions, which comprise a fatal strike to
kidney function. These findings suggest that the non-
invasive assessment of mitochondrial activity has potential
as a useful pathophysiological index for the prediction and
diagnosis of hepatitis and nephritis.
We recently developed novel PET probes with different
lipophilicity and affinity to MC-I, 2-tert-butyl-4-chloro-5-
{6-[2-(2-18F-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-
2H-pyridazin-3-one (18F-BCPP-EF; logD7.4 = 3.03; Ki =
2.31 nM), 2-tert-butyl-4-chloro-5-[6-(4-18F-fluorobutoxy)-
pyridin-3- ylmethoxy]-2H-pyridazin-3-one (18F-BCPP-BF;
logD7.4 = 4.27; Ki = 0.70 nM), and 2-tert-butyl-4-chloro- 5-
{6-[2-(2-11C-methoxy-ethoxy)-ethoxy]-pyridin-3-
ylmethoxy}-2H-pyridazin-3-one (11C-BCPP-EM; logD7.4 =
2.87; Ki = 4.70 nM) for the quantitative imaging of MC-I
in vivo [18, 19]. The capability of 18F-BCPP-EF to detect
neuronal damage as impaired MC-I activity has already
been evaluated in the brains of ischemic stroke [19, 20]
and Parkinsonism [21] animal models, as well as in the
brains of aged monkeys [22, 23]. Besides the brain and
heart, kinetic analyses using the tissue dissection method
have also indicated the strong uptake of these PET probes
in the liver and kidney of the rat [19].
In the present study, the capability of PET imaging
using 18F-BCPP-BF to detect acetaminophen-induced
changes in hepatitis and nephritis in the rat was evalu-
ated. The kinetic and distribution of 18F-BCPP-BF were
assessed using high-resolution animal PET in vivo. The
binding specificity of 18F-BCPP-BF to MC-I in the liver
and kidney was confirmed by the pre-administration of
rotenone, a specific MC-I inhibitor. The effects of acet-
aminophen on MC-I activity were assessed 2 and 24 h
after the administration of vehicle or acetaminophen at
a dose of 100 or 300 mg/kg. These PET imaging data in
the liver and kidney were further compared with the con-
ventional urinal and serum biochemical parameters of the
liver and kidney of rats treated with acetaminophen.
Methods
Animals and chemicals
The following experiments were approved by the Ethical
Committee of the Central Research Laboratory, Hamama-
tsu Photonics. Control male Sprague-Dawley rats (8 weeks
of age; 260–280-g body weight) were purchased from
Japan SLC, Inc. (Hamamatsu, Japan). Acetaminophen
was from Wako Pure Chemical Industry (Osaka, Japan).
Isoflurane and rotenone were purchased from Dainippon
Pharmaceutical (Osaka, Japan) and MP Biochemicals
LLC (Illkirch, France), respectively. The precursor of
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18F-BCPP-BF and its standard compound were obtained
from the NARD Institute (Amagasaki, Japan).
PET ligand synthesis
Positron-emitting fluorine-18 (18F) was produced by the
18O(p, n)18F nuclear reaction using the cyclotron (HM-18,
Sumitomo Heavy Industry, Ltd., Tokyo, Japan) at Hamama-
tsu Photonics PET center. Labeled compounds were syn-
thesized using a modified CUPID system (Sumitomo Heavy
Industry, Ltd., Tokyo, Japan). HPLC analyses of the labeled
compounds were performed on a GL-7400 low-pressure
gradient HPLC system (GL Sciences, Inc., Tokyo, Japan)
with a radioactivity detector (RLC-700, Hitachi Aloka
Medical, Inc., Tokyo, Japan).
18F-BCPP-BF was radiolabeled by nucleophilic 18F-
fluorination of the corresponding precursor as reported
previously [18–23]. The radiochemical purity and specific
radioactivity of 18F-BCPP-BF was more than 99% and
64.7 ± 25.3 GBq/μmol, respectively.
PET measurements
Four animals per group were used for PET imaging. In
order to evaluate the specific binding of 18F-BCPP-BF to
MC-I in the liver and kidney, vehicle or rotenone, a spe-
cific MC-I inhibitor, at a dose of 0.1 mg/kg in 10 mL of
vehicle (N,N-dimethylformamide/polyethylene glycol 400/
saline = 1/1/2) was continuously infused into control rats
through the tail vein for 1 h, followed by an injection of
18F-BCPP-BF into rats through the tail vein.
In order to evaluate the acute effects of acetamino-
phen, vehicle or acetaminophen at a dose of 100 or
300 mg/kg in 10 mL/kg of vehicle (saline containing
20% Tween-80) was intraperitoneally administered 2
or 24 h before the PET probe injection. Acetaminophen
doses were selected based on a previous study [24], which
showed that 300 mg/kg was the minimum dose needed to
induce toxicity in rats. The time points of PET imaging
were selected according to a previous report [10], which
revealed that nitrative modifications of mitochondrial en-
zymes 2 h after the administration of acetaminophen con-
tributed to mitochondrial dysfunctions, resulting in severe
necrosis 24 h after its administration.
Rats anesthetized by 1.5–2.0% isoflurane in O2 were
positioned prone on a fixation plate and placed in the
gantry hole of the PET scanner (SHR-7700, Hamamatsu
Photonics, Hamamatsu, Japan) [25]. After a transmission
scan for 15 min using a 68Ge-68Ga rotation rod source,
18F-BCPP-BF at ca. 15 MBq was intravenously injected
into each rat via the tail vein, and this was followed by
an emission scan with list mode data acquisition (every
1 ms) for 90 min. The body temperature of each animal
was monitored to record throughout the study using a
Thermo-Hygro Recorder (TR-72Ui, T&D Corporation,
Matsumoto, Japan).
The PET data obtained were reconstructed by Dy-
namic RAMLA (DRAMA) method with a Gauss filter of
1.0-mm FWHM and attenuation correction using the
transmission scan data. Dynamic images every 2 min for
the time activity curve (TAC) as well as summation im-
ages in the early (from 15 to 30 min after 18F-BCPP-BF
injection) and late (from 70 to 90 min) phases were re-
constructed. Since there were no information on the
TACs of 18F-BCPP-BF in the liver and kidney, we con-
ducted PET data acquisition up to 90 min after the injec-
tion. Then, we assessed which time period was suitable to
observe the effects of rotenone, a specific MC-I inhibitor,
by using PMOD software (PMOD Technologies Ltd.,
Zurich, Switzerland). Since the uptake levels of 18F-BCPP-
BF in these regions were high and relatively stable in early
phase (from 15 to 30 min) in control condition, and also
the inhibitory effects of rotenone on 18F-BCPP-BF uptake
showed the comparable results between the early (from 15
to 30 min) and late (from 70 to 90 min) phases, we de-
cided to apply averaged data in early phase (from 15 to
30 min) for the assessments of acetaminophen effects.
Standard uptake value (SUV) images were created as
follows:
SUV ¼ CT W sDinj
where CT is the tissue radioactivity (Bq/mL) obtained
from PET images, Ws is the body weight (g) of the rat
being examined, and Dinj is the injected dose (Bq) of
18F-BCPP-BF. Each summation SUV image was super-
imposed on the corresponding X-CT images obtained
using ClairvivoCT (Shimadzu Corporation, Kyoto, Japan).
Volumes of interest (VOIs) were selected on summation
images of the kidney (renal cortex and pelvis) and liver in
the early (from 15 to 30 min) and late (from 70 to 90 min)
phases and TACs were obtained from dynamic image data
in each organ as SUV by setting the early phase VOIs.
Physiological and biochemical assessments
In a separate study from PET measurements, physio-
logical and biochemical assessments were conducted on
four animals for each time and dosing condition. Body
weight measurements, urine collection, and blood sam-
pling were conducted 2, 6, and 24 h after the administra-
tion of acetaminophen. A rat was placed in a metabolic
cage on a 12/12-h light/dark cycle, and urine samples
were collected for 24 h and centrifuged to remove sus-
pended material, and the supernatants were analyzed to
measure total protein, creatinine, and N-acetyl-β-D-
glucosaminidase (NAG) using a biochemical automatic
analyzer (JCA-BM6010, JEOL Ltd., Tokyo, Japan). Blood
sample was collected from the tail vein, and the serum
fraction separated from the blood was used in assay of
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alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), lactate dehydrogenase (LDH), bilirubin
(BIL), and BUN using a biochemical automatic analyzer
(JCA-BM6010, JEOL Ltd., Tokyo, Japan).
Statistical analysis
Results are expressed as means ± SD. The significance of
differences was assessed by one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison
tests. A probability level of less than 5% (p < 0.05) was
considered to indicate significance.
Results
In addition to the liver, PET measurements (Fig. 1a) of
18F-BCPP-BF clearly imaged the renal cortex with
discrimination from the renal pelvis. The TACs of 18F-
BCPP-BF demonstrated reversible-type kinetics show-
ing peak uptake in by the renal cortex and liver and
constant uptake in the renal pelvis (Fig. 2a), revealing
strong uptake by the renal cortex (SUV = 8.12 ± 0.69),
moderate by the liver (4.40 ± 0.39) and renal pelvis
(4.17 ± 0.51), and weak by the bladder (0.88 ± 0.42, data
not shown) as averaged SUV from 15 to 30 min post-
injection (Fig. 2b). The uptakes of 18F-BCPP-BF calcu-
lated as averaged SUV from 70 to 90 min post-
injection were 6.29 ± 0.30, 3.75 ± 0.38, and 4.37 ± 0.64
in the renal cortex, liver, and renal pelvis, respectively
(Fig. 2c). With the pre-administration of rotenone at a
dose of 0.1 mg/kg/h, the uptake level of 18F-BCPP-BF
calculated as averaged SUV from 15 to 30 min post-
injection was markedly reduced in the liver (76.9%/p =
0.038 vs. control) and renal cortex (64.2%/p = 0.027 vs.
control) than in the control (Figs. 1b and 2b). The inhib-
ition degrees calculated as averaged SUV from 70 to
90 min post-injection were 67.9% (p = 0.003) and 52.2%
(p = 0.006) of each control in the liver and renal cortex,
respectively (Fig. 2c). Since two kinds of averaged SUV
data of 18F-BCPP-BF uptake in early (from 15 to 30 min
after the injection) and late (from 70 to 90 min) phases
showed similar results under control and rotenone con-
ditions, data analyses were conducted using early phase
averaged SUV.
As shown in Fig. 3, a dose-dependent reduction in the
uptake of 18F-BCPP-BF by the liver was induced 2 h
after the administration of acetaminophen (72.1%/p =
0.017 and 53.9%/p = 0.003 vs. control at 100 and
300 mg/kg, respectively) (Fig. 3, upper panel, and Fig. 4a),
whereas dose dependency in its uptake was not deter-
mined 24 h after the administration of acetaminophen
(81.4%/p = 0.049 and 80.5%/p = 0.002 vs. control at 100
and 300 mg/kg, respectively) (Fig. 3, lower panel, and
Fig. 4b). In the renal cortex, the reduced uptake of 18F-
BCPP-BF was detected 2 h after the administration of
acetaminophen at a high dose of 300 mg/kg (72.1%/p =
0.025 vs. control) (Fig. 3, upper panel, and Fig. 4a),
whereas a significant reduction in its uptake was observed
24 h after the administration of a low dose of 100 mg/
kg without dose dependency (83.4%/p = 0.038 and
79.5%/p = 0.009 vs. control at 100 and 300 mg/kg, re-
spectively) (Fig. 3, lower panel, and Fig. 4b). In the
renal pelvis, the reduced uptake of 18F-BCPP-BF was
detected at 300 mg/kg 2 h after the administration of
acetaminophen (56.6%/p = 0.027 vs. control) (Fig. 3,
upper panel, and Fig. 4a), whereas no significant reduc-
tion in its uptake was observed 24 h after (Fig. 3, lower
panel, and Fig. 4b).
Hepatic biochemical parameters indicated that AST,
ALT, and BIL significantly increased 24 h after the
acetaminophen treatment, but only at a dose of
300 mg/kg (322.3%/p < 0.001, 207.4%/p = 0.001, and
Fig. 1 PET-CT images of rat abdominal organs using 18F-BCPP-BF. Vehicle or rotenone (0.1 mg/kg) was continuously infused into control rats
through the tail vein for 1 h, followed by 18F-BCPP-BF injection into rat through the tail vein. PET scanning was conducted for 90 min, summation
PET data from 15 to 30 min were reconstructed for SUV images, and PET images were then superimposed on individual X-CT images. a Control.
b Rotenone
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186.2%/p = 0.034 vs. the corresponding control;
383.0%/p < 0.001, 224.6.4%/p = 0.001, and 233.3%/p =
0.034 vs. the corresponding 100 mg/kg), whereas their
levels did not show significant changes at a dose of
100 mg/kg (Fig. 5a–c). LDH did not show any signifi-
cant alterations after the acetaminophen treatment
from the control condition (Fig. 5d).
Nephritis biochemical parameters revealed that urinary
protein excretion was decreased (56.4%/p = 0.028 vs.
control; 46.9%/p = 0.017 vs. 100 mg/kg) 6 h after and in-
creased (128.9%/p = 0.027 vs. control; 143.0%/p = 0.027
vs. 100 mg/kg) 24 h after the acetaminophen treatment
at a dose of 300 mg/kg (Fig. 6a). Creatinine levels sig-
nificantly decreased after 6 h at a dose of 300 mg/kg
Fig. 2 Effects of rotenone on time activity curves (TACs) (a) and uptake of 18F-BCPP-BF at early (b) and late (c) phases by the liver and kidney of
the control rat. Vehicle or rotenone (0.1 mg/kg) was continuously infused into the control rats through the tail vein for 1 h, followed by the
18F-BCPP-BF injection into rats through the tail vein. PET scanning was conducted as described in the legend of Fig. 1. The volumes of
interest (VOIs) were set on the kidney (renal cortex and pelvis) and liver, and TACs were obtained in each organ as SUV (a). Averaged SUV
values from 15 to 30 min (b) and from 70 to 90 min (c) after the 18F-BCPP-BF injection were calculated from the data of time activity curves.
*p < 0.05 vs. vehicle
Fig. 3 Effects of acetaminophen on the uptake of 18F-BCPP-BF in the liver and kidney of the rat. Vehicle or acetaminophen at a dose of 100
or 300 mg/kg was intraperitoneally administered, and PET scanning was conducted using 18F-BCPP-BF 2 or 24 h after the administration of
acetaminophen. Summation PET data from 15 to 30 min were reconstructed for SUV images, and PET images were then superimposed on
individual X-CT images as described in the legend of Fig. 1
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Fig. 4 Effects of acetaminophen on the uptake of 18F-BCPP-BF in the kidney and liver of rats. Two (a) or 24 h (b) after the administration of vehicle or
acetaminophen at a dose of 100 or 300 mg/kg, PET scans were conducted as described in the legend of Fig. 1. Averaged SUV values from 15 to 30 min
after the 18F-BCPP-BF injection were calculated as described in the legend of Fig. 2. *p < 0.05 vs. vehicle
Fig. 5 Effects of acetaminophen on biochemical parameters for hepatic function in the rat. Blood samples were collected 2, 6, and 24 h after the
administration of acetaminophen, and the serum fraction separated from blood was used for the assay of ALT (a), AST (b), BIL (c), and LDH (d).
*p < 0.05 vs. vehicle, #p < 0.05 vs. 100 mg/kg acetaminophen
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(24.3%/p < 0.001 vs. control; 23.4%/p = 0.002 vs.
100 mg/kg) and returned to the vehicle level (Fig. 6b).
BUN did not show any significant alterations with the
acetaminophen treatment at any time (Fig. 6c). NAG
showed a significant increase 24 h after the acet-
aminophen treatment, but only at a dose of 300 mg/kg
(161.8%/p = 0.011 vs. control; 164.8%/p = 0.027 vs.
100 mg/kg), and did not show any significant changes
at a dose of 100 mg/kg (Fig. 6d).
Discussion
The present study demonstrated the capability of PET
imaging of MC-I activity using 18F-BCPP-BF for the
acute phase detection of hepatitis and nephritis induced
by an overdose of acetaminophen in rats. The uptake of
18F-BCPP-BF by the liver and kidney was significantly
reduced as early as 2 h after the administration of acet-
aminophen, whereas biochemical parameters in plasma
and urine started to be affected 6 h or later at the high
dose of 300 mg/kg.
The liver and kidney are highly energetic organs and
rich in mitochondria, and as expected, the present study
demonstrated the uptake of 18F-BCPP-BF by these two
organs. The strong uptake of 18F-BCPP-BF was detected
by the kidney, particularly by the renal cortex, while
weaker uptake by the renal pelvis was also observed.
This stronger renal cortical uptake may be attributed to
a disparity in blood flow between the cortex and pelvis
in the kidney; the cortical blood flow is fivefold greater
than pelvis blood flow [26]. However, this was unlikely
because reversible-type kinetics such as 18F-BCPP-BF
are generally expected to be less sensitive to blood flow
changes [27]. We previously reported the low cerebral
blood flow dependence of 18F-BCPP-EF, an analog of
18F-BCPP-BF, with reversible-type kinetics in the living
brains of stroke [20] and aged monkeys [22]. In addition,
the uptake of 18F-BCPP-BF by the kidney as well as
Fig. 6 Effects of acetaminophen on biochemical parameters for renal function in the rat. Blood and urine samples were collected 2, 6, and 24 h
after the administration of acetaminophen. Urine was centrifuged to remove suspended material and the supernatants analyzed to measure total
urinary protein (a), creatinine (b), and NAG (d). Blood samples were collected 2, 6, and 24 h after the administration of acetaminophen, and the
serum fraction separated from the blood was used for the assay of BUN (c). *p < 0.05 vs. vehicle, #p < 0.05 vs. 100 mg/kg acetaminophen
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the liver was significantly suppressed by the pre-
administration of rotenone, a specific MC-I inhibitor,
which fully inhibited the binding of MC-I PET probes
to MC-I in the heart and brain at a dose of 0.1 mg/kg
[19]. We previously reported that dose escalation of
more than 0.1 mg/kg was almost impossible because
of lethal effects on the cardiac function [19]. Taken to-
gether, these results confirmed that the uptake of 18F-
BCPP-BF reflected MC-I activity, not just blood flow
difference, in the liver and kidney.
One of the most interesting findings of the present
study was that the acute adverse effects of acetaminophen
on the liver and kidney were detectable as the reduced up-
take of 18F-BCPP-BF as early as 2 h after acetaminophen
dosing, whereas the conventional biochemical parameters
in plasma and urine commonly used in medical setting
started to be affected 6 h or later at the higher dose. These
results demonstrated that the non-invasive monitoring of
MC-I activity is a useful and valuable index with higher
sensitivity for hepatic and renal impairments. ALT and
AST have been recognized to reflect liver cell death, while
other parameters such as the prothrombin time and bili-
rubin show temporally losses and the later recovery of
liver functions. Proteinuria and serum parameters are still
the gold standard in the care of nephritis but are non-
specific; they only occur in the later phase of nephritis,
and up to 54% of patients with renal allograft rejection do
not present these clinical signs [28]. The invasive proced-
ure of biopsy, as the other gold standard, carries the risk
of significant organ injury as well as a potential mis-
diagnosis because of limited sampling sites. Thus, these
biomarkers cannot always be used to predict patient
outcomes at early time points of disease progression.
Functional imaging of the liver and kidney with PET
has been limited. A previous clinical PET study demon-
strated that although there was a significant difference
in renal blood flow, measured by 15O-H2O-PET, between
healthy subjects and patients with renal dysfunction,
renal blood flow was not significantly different in pa-
tients with moderate and severe disease [29]. In the mo-
lecular imaging of kidney function with PET, the activity
of glucose transporters (GLUT1, 3, and 4) has been ex-
pected to be assessed using 18F-FDG-PET even in the
kidney. However, 18F-FDG is not appropriate for imaging
glucose metabolism in the liver [30] or kidney [31]. The
proximal kidney tubules, which compose more than 90%
of the renal cortex, rely on fatty acids rather than glucose,
which is the substrate of MC-I and MC-III to generate
ATP, resulting in the low contribution of glucose utility in
the renal cortex (=low 18F-FDG uptake). Furthermore, al-
though glucose is completely reabsorbed in the proximal
tubules of the kidney, 18F-FDG is continuously excreted
into the tubular lumen and accumulates along the renal
collecting system, inducing strong radioactivity uptake in
the kidneys, urinary tract, and bladder. In contrast, its ex-
clusive accumulation in the renal cortex suggests that
18F-BCPP-BF in the glomerular filtrate is reabsorbed by
active transport in the proximal convoluted tubule. This
accounts for the absence of observable urinary tracer
activity in the intrarenal collecting system. 2-Deoxy-2-
18F-fluororibose (18F-2-DFR), which accumulates pref-
erentially in the liver through the ribose salvage pathway,
has been proposed for the imaging of liver function [30].
Acetaminophen at 300 mg/kg, which is a toxic dose for
mice, caused only an approximately 20% reduction in 18F-
2-DFR uptake by the liver. In contrast, the present study
demonstrated that MC-I activity in the liver assessed
using 18F-BCPP-BF showed an approximately 50% re-
duction by acetaminophen at the same dose of 300 mg/kg
in rats, which are more resistant to acetaminophen than
mice [31, 32].
Dysfunctions in mitochondrial oxidative processes
after toxic doses of acetaminophen have been observed
in rodents since the 1980s [33]. Early findings suggested
that rats were more resistant to acetaminophen toxicity
than mice, leading to the assumption that rats were not
human-relevant species as an acetaminophen liver injury
model [31, 32]. A recent study indicated that although
overall acetaminophen metabolism was similar in both
species, mitochondrial protein adducts were significantly
lower in rats, which limits mitochondrial dysfunction
and prevents oxidative stress and peroxynitrite forma-
tion in rats [33]. However, the present results demon-
strated that MC-I activity in the rat liver measured using
18F-BCPP-BF was impaired by acetaminophen, even at a
low dose of 100 mg/kg, a dose at which no apparent
effects on hepatic function have been indicated in pre-
vious studies [24, 31, 32]. Dose-dependent reductions
in 18F-BCPP-BF were observed at early as 2 h after
acetaminophen dosing, at which the levels of AST,
ALT, and bilirubin in plasma and histological liver damage
remained unchanged. These results suggest that MC-I ac-
tivity measured using 18F-BCPP-BF is more sensitive than
conventional biochemical and histological parameters.
An overdose of acetaminophen induces acute hepato-
toxic and nephrotoxic effects with massive hepatic cen-
trilobular necrosis and acute renal failure, respectively,
while there is evidence to show that the molecular basis
of nephrotoxicity may differ from that of hepatotoxicity
because NAC protects against hepatotoxicity, but not
nephrotoxicity [3]. The present study also revealed dose
range differences in acetaminophen-induced reductions
in the uptake of 18F-BCPP-BF between the liver and
kidney. Thus, a decrease in the uptake of 8F-BCPP-BF
by the liver was observed, even with the low dose of
100 mg/kg, whereas a reduction in its uptake by the
kidney required the administration of acetaminophen at
higher doses of 300 mg/kg and more.
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The increased generation of ROS within the mito-
chondrial electron transport chain is considered to be
involved in pathogenic and drug-induced hepatitis and
nephritis. In early stage of diabetes, mitochondrial fatty
acid oxidation was found to be the source of increased
net ROS production in the kidney tubule of the rat [34].
Although cisplatin is a widely used chemotherapeutic
agent for cancers, its clinical use is limited due to its
nephrotoxicity including acute kidney injury with elevated
serum creatinine and BUN levels [35]. The mechanisms
underlying cisplatin-induced nephrotoxicity remain un-
clear; it has been shown to induce impairments in energy
metabolism and apoptosis in the mitochondria of the rat
kidney [35]. Collectively, these findings and the present
results indicate the potential of PET imaging of MC-I
to become a useful diagnostic technique for drug-induced
hepatotoxicity and nephrotoxicity.
One limitation of the present study was that 18F-
BCPP-BF resulted in the slightly greater accumulation of
radioactivity in bone with time, suggesting its instability
with defluorination [19]. A common mechanism under-
lying 18F-fluoride formation is P-450-mediated hydroxyl-
ation occurred at 18F-fluorine-substituted carbon followed
by spontaneous elimination [36]. However, significant
bone uptake occurred slowly at the later phase of 60 min
after the 18F-BCPP-BF injection [19], and the present
study confirmed that imaging of kidney and liver with
18F-BCPP-BF required only 30 min after the injection.
In addition, clinical assessment in human [37] as well
as our previous animal study on mice [38] demonstrated
that the injection of 18F-fluoride for bone scans did not ac-
cumulate in the kidney or liver, but strongly accumulated
in the bladder. These results indicate that 18F-BCPP-BF is
applicable to the quantitative imaging of MC-I activity in
the renal cortex and liver.
Conclusions
In conclusion, the present study demonstrated that PET
imaging of MC-I has potential as a useful index for the
non-invasive detection of hepatic and renal dysfunctions
induced by an overdose of acetaminophen in the living
body. These results suggested that, besides pathogenic hepa-
titis and nephritis, PET imaging of MC-I using 18F-BCPP-
BF will become a useful diagnostic technique for hepatotox-
icity and nephrotoxicity induced by other kinds of drugs
such as cisplatin discussed above. In addition to diagnoses,
PET imaging of MC-I may also be useful for monitoring the
therapeutic effects of candidate agents for hepatic and neph-
ritic diseases in vivo.
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